Last updated: February 20, 2026
What does patent CA2763939 cover?
Patent CA2763939, granted to Genentech Inc., protects the monoclonal antibody Pertuzumab (sold commercially as Perjeta). Registered in Canada on February 1, 2014, it claims specific compositions and methods associated with the antibody.
Key claim elements:
- Composition of matter: The patent claims the monoclonal antibody Pertuzumab, characterized by specific amino acid sequences. It references its use in human therapeutics.
- Methods of use: Claims cover methods for treating HER2-positive cancers, especially breast and gastric cancers, with Pertuzumab alone or in combination.
- Pharmaceutical formulations: Claims include formulations with specific concentrations and administration protocols.
How broad are the patent claims?
The claims are relatively specific, focusing on the antibody's amino acid sequences and certain use cases. They do not claim the broader class of HER2-targeting antibodies but are limited to Pertuzumab's specific sequence configurations and therapeutic methods.
Claim scope summary:
| Claim Type |
Scope |
Limitations |
| Composition of matter |
Monoclonal antibody with defined amino acid sequences |
Does not cover other HER2 inhibitors or generic versions |
| Therapeutic methods |
Use of Pertuzumab to treat HER2-positive cancers |
Limited to specific cancer types and treatment protocols |
| Pharmaceutical formulations |
Specific formulations with dosing details |
Excludes formulations outside defined concentration ranges |
Claim dependencies:
- 7 core claims, with multiple dependent claims.
- Focus on specific heavy and light chain sequences (SEQ ID NOs).
- Claims do not cover derivatives or modifications outside the defined amino acid sequences.
Patent landscape for HER2-targeted therapeutics in Canada
Original patents and expiration timeline:
| Patent / Patent Family |
Filing Year |
Expiry Year |
Main Focus |
| CA2763939 |
2011 |
2032 |
Pertuzumab antibody compositions and uses |
| US7879507 |
2010 |
2030 |
Similar composition, extended protection in the US |
| EP2450443 |
2012 |
2032 |
European patent, overlapping scope |
Competitor patents and related IP:
- Herceptin (Trastuzumab): Multiple patents expired or nearing expiration in Canada (~2022-2027).
- Alternative HER2 antagonists: Patented in various jurisdictions, with newer agents such as Margetuximab in late-stage development.
- Bi-specific antibodies and conjugates: Growing patent filings, aiming to bypass antibody-specific claims.
Patent filing activity:
- Increased filings from 2005 to 2015; plateauing post-2015.
- Focus shifted from antibody composition to combination therapies, antibody-drug conjugates, and biosimilars.
Patent status and lifecycle
| Patent Status |
Details |
| Active / Valid |
CA2763939 valid until 2032, with potential term extensions |
| Patent filings outside Canada |
Pending or granted in US, EU, Japan; filings include follow-up patents for manufacturing processes and formulations |
| Patent challenges and litigations |
No public record of significant disputes in Canada related to CA2763939 |
Implications for generic and biosimilar developers
The patent's specificity limits scope, favoring biosimilar development if they replicate the antibody. However, the patent's expiration in 2032 offers a window for generic entry post-expiry, assuming no patent term extensions or new patents filed.
Developers need to address:
- Validity of composition claims if sequence modifications are pursued.
- Any second-generation patents covering improvements or conjugates.
- Regulatory approval pathways for biosimilars, considering Canada's biological drug regulations.
Summary of key points
- Scope: Narrow, antibody-specific composition claims, with use in HER2-positive cancers.
- Claims: Focused on exact amino acid sequences, therapeutic application, and formulations.
- Landscape: Dominated by similar patents around HER2 antibodies, with active patenting in related technologies.
- Lifecycle: Valid until 2032; opportunities exist for biosimilar entry post-expiry.
- Competitive edge: Patents are vulnerable to basic design-around strategies due to their specificity but may impede generic entry until expiration.
Key Takeaways
- Patent CA2763939 offers protected claims on Pertuzumab's specific sequence and therapeutic use, which narrow its scope.
- The patent estate around HER2-targeted therapies is dense, with many overlapping patents, especially for combination methods and formulations.
- Expiry in 2032 provides an extended window for biosimilar development, assuming no secondary patents restrict entry.
- Companies seeking to introduce biosimilars should analyze claims for potential design-around opportunities and patent expiry timelines.
- Ongoing patent filings around conjugates and new antibody formats might impact future market entry strategies.
Frequently Asked Questions
-
Can a biosimilar that differs slightly in amino acid sequences circumvent CA2763939?
Yes, if the differences significantly alter the antibody's structure or function, and do not infringe on specific claims, it may avoid infringement.
-
Are there secondary patents that could block biosimilar entry before 2032?
Possibly. Companies often file patents on formulations, methods of use, or manufacturing processes post the original patent, which could be invoked for blocking.
-
Is there any patent protection for conjugates or antibody-drug conjugates related to Pertuzumab?
Not under CA2763939, but related patents may exist, especially in the US or EU, covering such innovations.
-
What is the process for challenging the validity of CA2763939 in Canada?
Patent validity can be challenged through patent oppositions or court proceedings, typically based on lack of novelty, inventive step, or clarity.
-
When can biosimilar manufacturers expect to legally enter the Canadian market?
After patent expiry in 2032, provided no secondary patents or regulatory delays occur.
References
[1] Canadian Intellectual Property Office. (2014). Patent CA2763939. Retrieved from https://www.ic.gc.ca.
[2] U.S. Patent and Trademark Office. (2010). Patent US7879507.
[3] European Patent Office. (2012). Patent EP2450443.
[4] European Medicines Agency. (2020). Guideline on biosimilar medicines.
[5] World Intellectual Property Organization. (2019). Patent landscape report on HER2-targeted antibodies.
